Back to top

Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on SPRY stock, giving a Buy rating on September 6. Lachlan Hanbury ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ARS Pharmaceuticals, Inc. (SPRY)